ensifentrine COPD
Selected indexed studies
- Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD. (Int J Chron Obstruct Pulmon Dis, 2023) [PMID:37533771]
- Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). (Am J Respir Crit Care Med, 2023) [PMID:37364283]
- Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis. (Respir Med, 2025) [PMID:39557208]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD. (2023) pubmed
- Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). (2023) pubmed
- Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis. (2025) pubmed
- Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies. (2025) pubmed
- Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases. (2025) pubmed
- Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. (2025) pubmed
- Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective. (2025) pubmed
- Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments. (2025) pubmed
- Ensifentrine (Ohtuvayre) for COPD. (2024) pubmed
- Advancing COPD management through novel pharmacological agents: ensifentrine and dupilumab. (2025) pubmed